In vivo near-infrared fluorescence and SPECT-CT imaging of colorectal Cancer using the bradykinin B2R-specific ligand icatibant

Qin, Kaili; Xin, Suling; Li, Gang; Zhou, Kuncheng; Pan, Rongbin; Chen, Shuying; Tao, Tianming; Li, Changsheng; Ji, Tao; Han, Ray P. S.; Tu, Yuanbiao

doi:10.1016/j.jphotobiol.2023.112648

Cited by 6 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several issues have to be considered for the clinical translation of this noninvasive pathological diagnosis strategy. First, the clinical experience revealed that FDA-approved E7406 and vandetanib could induce unexpected toxic effects, such as cutaneous and oral adverse reactions, arrhythmia, hypertension, and diarrhea. ,,, These toxic side effects may be due to its poor solubility and metabolism in vivo. The structure of fluorescence probes and approach of administration could be optimized for better metabolism characteristics and reduced adverse reactions.…”

Section: Discussionmentioning

confidence: 99%

“…Conventional wide-field FE has limited diagnostic effectiveness due to the macroscale illumination of colorectal tissues but not microscale pathological analysis. As is well known, fluorescence imaging is difficult to use for diagnosis of human diseases, due to the shallow penetration depth, the scattering of the emission, and the intense background signals from autofluorescence, which results in false positive detection results. − To overcome these limits, our home-built multi-channel confocal laser endomicroscopy (CLE) is an innovative diagnostic tool providing real-time, multichannel, and microscale (0.7 μm) fluorescence imaging. Therefore, a combination of this CLE system, the dual biomarkers and FITC for reference enables concurrent in vivo hypostatic histology of microstructural, monitoring levels, and location of molecular biomarkers.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

In Vivo Staging the Progression of Colitis and Associated Cancer by Concurrent Microimaging of Key Biomarkers

Han,

Li,

Wang

et al. 2023

Anal. Chem.

Self Cite

View full text Add to dashboard Cite

Currently colorectal cancer (CRC) staging (colitis, adenoma, and carcinoma) mainly relies on ex vivo pathologic analysis requiring an invasive surgical process with limited sample collection and increased metastatic risk. Thus, in vivo noninvasive pathological diagnosis is extremely demanded. By verifying the samples of clinical patients and CRC mouse models, it was found that vascular endothelial growth factor receptor 2 (VEGFR2) was barely expressed in the colitis stage and only appeared in adenoma and carcinoma stages with obvious elevation, while prostaglandin E receptor 4 (PTGER4) could be observed from colitis to adenoma and carcinoma stages with a gradient increase of expression. VEGFR2 and PTGER4 were further chosen as key biomarkers for molecular pathological diagnosis in vivo and corresponding molecular probes were constructed. The feasibility of in vivo noninvasive CRC staging by concurrent microimaging of dual biomarkers using confocal laser endoscopy (CLE) was verified in CRC mouse models and further confirmed by ex vivo pathological analysis. In vivo CLE imaging exhibited the correlation of severe colonic crypt structural alteration with a higher biomarker expression in adenoma and carcinoma stages. This strategy shows promise in benefiting patients undergoing CRC progression with in-time, noninvasive, and precise pathological staging, thus providing valuable guidance for selecting therapeutic strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

In Vivo Staging the Progression of Colitis and Associated Cancer by Concurrent Microimaging of Key Biomarkers

Han,

Li,

Wang

et al. 2023

Anal. Chem.

Self Cite

View full text Add to dashboard Cite

show abstract

“…With that, healthcare workers can better design treatment plans to maximize therapeutic efficiency. Besides using NIR-responsive nanoassemblies for breast cancer theranostics, its widespread application in cancer treatment stretches out to colorectal, [93,99] ovarian, [100] bladder, [101] oral cancer, etc. [102] Hence, it is anticipated that the integration of diagnostic and therapy properties in a single NIR-responsive nanoassemblies has strong potential in future clinical applications.…”

Section: Imagingmentioning

confidence: 99%

Light‐Responsive Nanoassemblies: Advancing Biomedical Innovation

Sia,

Tey,

Low

2024

Adv Funct Materials

View full text Add to dashboard Cite

The integrative use of light and nanoassemblies has made a profound impact in the biomedical field for diagnosis, drug delivery, and phototherapy. Recent advances in the development of light‐responsive nanoassemblies showcase their capabilities in facilitating targeted diagnosis and therapy with minimal invasiveness, shaping the future of personalized medicine. In this work, the fundamental differences between types of light in biomedical applications, and the application of light‐responsive nanoassemblies in diagnosis and therapy are described, their biosafety profile is overviewed and discussed, and the translational challenges and potential clinical outlook of this emerging field are outlined.

show abstract

“…The development of molecular probes with both high specificity and sensitivity for visualizing tumors and their boundaries remains a persistent challenge in the field of fluorescence-guided surgery. Although the study of probes targeted for CRC is actively ongoing, nearly all antibody-conjugated probes and small molecules designed for CRC-targeted imaging are still in the preclinical and clinical trial stages. ,− GE-137, a cyclic peptide fluorescent probe targeting c-Met, has demonstrated utility in the detection of both early and advanced CRC. , However, the presence of two disulfide bonds significantly elevates the complexity and expense associated with its synthesis. Fluorescent probes utilizing the small-molecule c-Met inhibitor Crizotinib exhibit potential for CRC detection, but their substantial nonspecific accumulation in liver tissue and small intestine tissue impedes the imaging outcomes. , High uptake of the c-Met targeting fluorescent probe QQT*-IRDye800 in liver tissue may render it ineffective for the diagnosis of CRC liver metastases …”

Section: Introductionmentioning

confidence: 99%

Novel Near-Infrared Fluorescent Probe for Hepatocyte Growth Factor in Vivo Imaging in Surgical Navigation of Colorectal Cancer

Chen,

Li,

Pan

et al. 2024

Anal. Chem.

Self Cite

View full text Add to dashboard Cite

Despite recent advancements in colorectal cancer (CRC) treatment, the prognosis remains unfavorable primarily due to high recurrence and liver metastasis rates. Fluorescence molecular imaging technologies, combined with specific probes, have gained prominence in facilitating real-time tumor resection guided by fluorescence. Hepatocyte growth factor (HGF) is overexpressed in CRC, but the advancement of HGF fluorescent probes has been impeded by the absence of effective HGF-targeting small-molecular ligands. Herein, we present the targeted capabilities of the novel V-1-GGGK-MPA probe labeled with a near-infrared fluorescent dye, which targets HGF in CRC. The V-1-GGGK peptide exhibits high specificity and selectivity for HGF-positive in vitro tumor cells and in vivo tumors. Biodistribution analysis of V-1-GGGK-MPA revealed tumor-specific accumulation with low background uptake, yielding signal-to-noise ratio (SNR) values of tumor-to-colorectal >6 in multiple subcutaneous CRC models 12 h postinjection. Quantitative analysis confirmed the probe’s high uptake in SW480 and HT29 orthotopic and liver metastatic models, with SNR values of tumor-to-colorectal and -liver being 5.6 ± 0.4, 4.6 ± 0.5, and 2.1 ± 0.3, 2.0 ± 0.5, respectively, enabling precise tumor visualization for surgical navigation. Pathological analysis demonstrated the excellent tumor boundaries discrimination capacity of the V-1-GGGK-MPA probe at the molecular level. With its rapid tumor targeting, sustained tumor retention, and precise tumor boundary delineation, V-1-GGGK-MPA merges as a promising HGF imaging agent, enriching the toolbox of intraoperative navigational fluorescent probes for CRC.

show abstract

In vivo near-infrared fluorescence and SPECT-CT imaging of colorectal Cancer using the bradykinin B2R-specific ligand icatibant

Cited by 6 publications

References 33 publications

In Vivo Staging the Progression of Colitis and Associated Cancer by Concurrent Microimaging of Key Biomarkers

In Vivo Staging the Progression of Colitis and Associated Cancer by Concurrent Microimaging of Key Biomarkers

Light‐Responsive Nanoassemblies: Advancing Biomedical Innovation

Novel Near-Infrared Fluorescent Probe for Hepatocyte Growth Factor in Vivo Imaging in Surgical Navigation of Colorectal Cancer

Contact Info

Product

Resources

About